(Q43257937)

17 November 2017

title

Thyroid gland: Antithyroid therapy--best choice of drug and dose (English)

1 reference

17 November 2017

Jayne A Franklyn

1

1 reference

17 November 2017

language of work or name

1 reference

1 November 2009

1 reference

Nature Reviews Endocrinology

17 November 2017

published in

1 reference

17 November 2017

volume

5

1 reference

17 November 2017

issue

11

1 reference

17 November 2017

page(s)

592-594

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

17 November 2017

1 reference

Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

A systematic review of drug therapy for Graves' hyperthyroidism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

Putting propylthiouracil in perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.201

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2009.201

1 reference

17 November 2017

1 reference